Plain-English translation of NCT06513624 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a combination of two medications: , which blocks a specific pathway that helps cancer grow, and , which helps your immune system recognize and attack cancer cells. The goal is to see if giving these two treatments together is safe and effective for women with advanced ovarian cancer that has become resistant to platinum-based chemotherapy.
Most women with platinum-resistant ovarian cancer have limited treatment options, and many tumors are 'cold'—meaning the immune system isn't effectively fighting them. This trial is exploring whether this medication combination can warm up these cold tumors and make them responsive to immune therapy, potentially offering new hope for patients who have run out of standard options.
You likely qualify if…
You likely don't qualify if…
You will come in for screening tests including blood work, imaging scans, and possibly a bone density scan. If you qualify, you'll take as a tablet by mouth every other day, and receive as an intravenous infusion every 3 weeks, along with bone-protective medications. Treatment is organized in 21-day cycles, and you'll have regular check-in visits to monitor how well the treatment is working and watch for side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Singapore